Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31564004 | 0.82 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL192119 | 0.78 | ALDH1A1 (0.45) | ALDH1A1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL14680120 | 0.76 | ALDH1A1 (0.45) | ALDH1A1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL4918543 | 0.74 | NPSR1 (0.43) | ALDH1A1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL15624358 | 0.74 | KMT2A (0.55) | ALDH1A1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL12282468 | 0.73 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL12282460 | 0.73 | MEN1 (0.43) | ALDH1A1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL12281391 | 0.73 | ALDH1A1 (0.42) | ALDH1A1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL30479647 | 0.72 | ALDH1A1 (0.42) | ALDH1A1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL12282151 | 0.72 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577367-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | ALDH1A1 3110/4885KMT2A 769/4885MEN1 3492/4885 |
| US-10577367-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | ALDH1A1 3110/4885KMT2A 769/4885MEN1 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.